International Stem Cell Corp. Prepares to Up-List, Tightens Share Structure Ahead of Landmark Parkinson’s Clinical Trial

August 5, 2015 (Investorideas.com stocks newswire) With the success of its nine-month GLP safety (tumorigenicity) and biodistribution animal model study in Parkinson’s Disease (PD) showing a completely clean record, as zero tumor growth was observed across …

[Read the full article here]

Comments are closed.